SquareMind Raises $18M for AI Skin-Scanning Robot

SquareMind Secures $18 Million to Bring AI-Powered Full-Body Skin Scanning Robots to Dermatology Clinics Worldwide

Skin cancer is one of the most common and, importantly, one of the most preventable forms of cancer in the world — provided it is caught early enough. For decades, dermatologists have relied on handheld tools and the sheer weight of clinical experience to detect suspicious moles or lesions across a patient's entire body. The process is time-consuming, manually intensive, and inevitably prone to human error. But a Paris-based startup is now making a compelling case that robotics and artificial intelligence can dramatically transform how full-body skin examinations are conducted. SquareMind, the company behind the world's first full-body dermoscopic imaging robot named Swan, has announced that it has raised $18 million in funding, a major milestone that is already generating buzz across the AI funding news landscape and signalling a broader shift in how the medical technology world is approaching early cancer detection.

This latest AI funding round was led by Sonder Capital, a California-based venture fund co-founded by Fred Moll, a name that commands considerable respect in the medical device and robotics world. Moll was one of the co-founders of Intuitive Surgical, the company behind the famous da Vinci surgical robot, making his involvement in SquareMind particularly noteworthy. His backing is not just financial — it carries with it decades of domain expertise, a proven track record of bringing complex medical robotics to clinical settings, and a deep understanding of the regulatory and commercial challenges that come with selling technology into healthcare environments. When a figure with Moll's background decides to lead a funding round, the industry takes notice, and SquareMind's $18 million raise is no exception.

Alongside Sonder Capital, the funding round drew participation from a diverse and strategically aligned group of investors. The French government's Deeptech 2030 Fund, managed through Bpifrance, was among the backers — a move that reflects France's growing ambition to position itself as a global leader in deep technology and life sciences innovation. Other notable participants included Adamed Technology, Calm/Storm Ventures, and Teampact Ventures. Together, this investor syndicate brings not just capital but an extensive network of industry relationships, regulatory experience, and international market access that SquareMind will need as it prepares to scale commercially across Europe and the United States.

The Vision Behind SquareMind and Swan

SquareMind was founded in 2019 by Ali Khachlouf and Tanguy Serrat, two entrepreneurs who identified a glaring gap at the intersection of dermatology, robotics, and artificial intelligence. Their core insight was simple but powerful: while dermatoscopy — the practice of examining skin lesions up close using magnification and light — is the gold standard for identifying early-stage skin cancers, it has always been limited by the fact that a doctor can only examine one mole at a time. For a patient with dozens or even hundreds of moles spread across their entire body, a comprehensive manual examination can take considerable time, and even then, there is always the risk that something gets overlooked.

Swan, SquareMind's flagship product, was designed to solve precisely this problem. The robot functions as an augmented dermatoscope, capturing standardised, high-resolution dermoscopic images of the entire body surface rather than a single lesion. In practice, the patient enters a private examination room and simply stands before the device. From there, visual and audio prompts guide them through a series of positions and postures. A robotic arm moves around the body, systematically capturing images of every accessible area of the skin. The entire process is contactless — the robot never physically touches the patient — and is completed within a matter of minutes. The images produced match the resolution and level of detail that a dermatologist would normally see when examining individual moles with a handheld dermoscope, but cover the full body rather than isolated spots.

Once the imaging is complete, SquareMind's AI software takes over. The system processes the images, cross-references them against previous scans, and tracks any moles that are new or have changed in appearance over time. Crucially, the software is designed to flag potential risks for the attending dermatologist to review, rather than replacing the physician's judgement entirely. Dermatologists retain full authority over all diagnostic decisions. Swan effectively acts as an intelligent, tireless assistant that handles the routine visual survey work so that doctors can focus their expertise on interpretation and clinical decision-making. For patients, this means more thorough and consistent monitoring. For dermatologists, it means a significant reduction in manual burden without any compromise to clinical standards.

A Crowded but Largely Unsolved Market

The dermatology imaging market is not without existing solutions, and SquareMind's team is well aware of what has come before them. Several companies have built tools that address different parts of the skin examination workflow. Canfield Scientific's VECTRA WB360 offers total body photography. MoleSafe operates a total-body photography system focused on mole mapping and monitoring. 3Derm has developed a remote imaging platform that allows certain types of skin conditions to be assessed without in-person visits. Each of these platforms has found its niche, and each represents a genuine advancement over purely manual methods.

However, according to SquareMind, none of these existing solutions offer the combination of features that Swan brings together. Specifically, no other commercially available system provides both full-body dermoscopic resolution — the level of close-up detail needed to evaluate individual moles — and robotic automation in a single integrated workflow. What this means in practical terms is that a dermatologist using existing tools either gets high-resolution imaging of individual lesions but must manually select which ones to examine, or gets an overview of the entire body but at a resolution that doesn't meet dermoscopic standards. Swan closes this gap by delivering both simultaneously, in a fully automated process that fits naturally into existing clinical environments.

This is a significant differentiator, and it is one of the core reasons that AI funding news around this round has attracted attention beyond the usual startup circles. The medical robotics and AI-assisted diagnostics space has seen a wave of investment over the past several years, but truly differentiated products that solve a problem no prior technology has adequately addressed remain relatively rare. SquareMind appears to have found that kind of genuinely novel positioning, which goes a long way toward explaining why a seasoned investor like Fred Moll chose to back the company at this stage.

Regulatory Clarity and the Path to Commercial Launch

One of the most common barriers to adoption in the medical device world is regulatory uncertainty. Healthcare providers are understandably cautious about introducing new technologies into clinical workflows, and the absence of regulatory clearance can make even the most promising innovations difficult to commercialise. SquareMind has made notable progress on this front. Swan is currently listed as a Class I 510(k)-exempt device by the US Food and Drug Administration, which means it can be marketed and sold in the United States without requiring the more extensive premarket approval process typically associated with higher-risk devices. In Europe, Swan holds CE marking, the standard conformity certification required for medical devices to be sold across European Union member states.

This dual regulatory positioning is strategically important. It means that SquareMind is not waiting on regulatory decisions to begin commercialising its technology — it can move forward with sales and deployment in both major markets essentially immediately. The newly raised $18 million will be directed toward exactly that goal. The company has outlined plans to grow its commercial team to support market entry efforts, expand its engineering team to continue iterating on the technology, and build out a customer success and support function that can serve the needs of clinical customers across geographies. All of this points to a company that has moved decisively from the development and validation phase into the execution and scaling phase.

Given that the global skin cancer diagnostics market is projected to continue growing as ageing populations in developed countries face rising incidence rates of melanoma and other skin cancers, the timing of this AI funding round appears well-calibrated. Early detection remains the single most powerful lever in improving patient outcomes, and any technology that can make thorough, consistent full-body skin monitoring more accessible and more scalable is entering a market with genuine and urgent demand.

France's Deeptech Momentum and the Broader AI Funding Landscape

SquareMind's funding round does not exist in isolation. It is part of a broader and accelerating trend of significant AI funding flowing into French deeptech companies, a trend that has gathered substantial momentum over the past year and shows no signs of slowing down. France has invested heavily in cultivating a deeptech ecosystem — through government programmes, dedicated investment vehicles like Bpifrance's Deeptech 2030 Fund, and a growing network of world-class research institutions and engineering talent.

The AI funding news coming out of France recently reflects this ambition at scale. Mistral AI, one of Europe's most prominent large language model companies, secured $830 million in debt financing to build out AI infrastructure across the continent. Holistic AI, a company focused on AI governance and risk management, raised $200 million in a high-profile round backed by investors who see Europe's regulatory environment as a structural advantage for responsible AI development. Against this backdrop, SquareMind's $18 million raise represents the life sciences and medical robotics chapter of the same broader story — that France, and Europe more broadly, is building globally competitive AI companies across multiple verticals, not just in the enterprise software and foundation model categories that have dominated headlines elsewhere.

For The AI World Organization, developments like SquareMind's funding round are precisely the kind of AI funding news that illustrate how artificial intelligence is moving beyond digital applications into the physical world of healthcare, diagnostics, and clinical robotics. The integration of AI into medical devices is not a future prospect — it is happening now, and it is being backed by serious capital from credible investors who understand both the technology and the market.

What This Means for the Future of Dermatology

The implications of Swan's technology extend well beyond the immediate context of mole mapping and skin cancer screening. If SquareMind's approach gains traction — which the composition of its investor base and its regulatory status both suggest is plausible — it could help establish a broader template for how AI and robotics can be embedded into routine preventive care. Today, full-body skin examinations are often underutilised, in part because they are time-consuming and resource-intensive for both patients and providers. A technology that makes comprehensive screening faster, more consistent, and less dependent on individual physician availability could meaningfully increase the frequency and thoroughness of skin cancer surveillance across entire patient populations.

There is also a data dimension worth considering. As Swan is deployed across clinical settings and accumulates imaging data over time, the AI models underpinning the system will have access to an increasingly rich dataset for training and refinement. This creates a compounding advantage — the more the system is used, the better it gets at identifying subtle changes and flagging meaningful patterns. In a field where early detection can literally be the difference between life and death, improvements in sensitivity and specificity driven by real-world data have profound clinical consequences.

It is also worth noting the broader societal dimension of what SquareMind is building. Skin cancer disproportionately affects individuals who lack regular access to specialist dermatology care, whether due to geography, cost, or wait times. A robotic system that can be deployed in a wider range of clinical settings — not just major academic medical centres with large dermatology departments — could help democratise access to high-quality skin monitoring. If Swan can be operated by trained clinical staff rather than requiring a specialist dermatologist to perform every scan, it could significantly expand the reach of thorough skin examinations to underserved patient populations.

For followers of AI funding news and medical innovation, SquareMind's $18 million round is a story worth watching closely. The company has built something technically differentiated, secured it appropriately from a regulatory standpoint, attracted credible and experienced investors, and identified a market where the need for better solutions is both clear and commercially significant. The coming months, as the company builds out its teams and begins its commercial push across Europe and the United States, will be a test of whether the technology performs as well in real-world clinical environments as it does on paper — but based on everything in the current AI funding landscape, the conditions for success look genuinely favourable.